LY9 and Miyoshi myopathy: For instance, CAR-T cells targeting signaling lymphocytic activation molecule F7 (SLAMF7) and signaling lymphocytic activation molecule F3 (SLAMF3) for untreated and chemo-resistant MM patients have shown efficient killing in both in vitro and in vivo experiments.